{"id":"W2601086841","doi":"10.1200/jco.2014.32.15_suppl.8051","title":"A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Oncology; ERBB3; Progression-free survival; Log-rank test; Epidermal growth factor receptor; Cancer; Chemotherapy; Survival analysis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02234687,0.0001813362,0.003173801,0.0005266825,0.0000321895,0.00001032174,0.0002553663,0.0004081517,0.000136903],"category_scores_gemma":[0.02591047,0.000126434,0.0003906358,0.0004765582,0.0004721965,0.0001346731,0.00005980082,0.001804425,0.000004796211],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002824679,"about_ca_system_score_gemma":0.002016685,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001418694,"about_ca_topic_score_gemma":0.0001246023,"domain_scores_codex":[0.9904707,0.003334631,0.004587224,0.0002705072,0.0009599234,0.0003770155],"domain_scores_gemma":[0.9893995,0.006133808,0.002778428,0.0002151615,0.001156201,0.0003169067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8792655,0.01205944,0.07852249,0.00007236067,0.0001720232,0.0001678123,0.000241808,0.00002740348,0.0006009666,0.0002084728,0.0004575294,0.0282042],"study_design_scores_gemma":[0.9005595,0.06469207,0.0292445,0.0004473744,0.0001489959,0.00001930862,0.00006125165,0.0007271378,0.00008492719,0.0004675935,0.003436897,0.0001104135],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993249,0.0000884234,0.0001822836,0.002495848,0.0007985824,0.001395253,0.000001747955,0.000006255347,0.001782609],"genre_scores_gemma":[0.9965062,0.0001472407,0.002083422,0.0004024903,0.0007446156,0.00001684644,0.00002122182,0.00002679608,0.00005115907],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05263262,"threshold_uncertainty_score":0.9822947,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.12330918582681,"score_gpt":0.5359127661219609,"score_spread":0.4126035802951509,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}